Ceruloplasmin replacement therapy

Aceruloplasminemia is a monogenic disease caused by mutations in the ceruloplasmin gene that result in loss of protein ferroxidase activity. Ceruloplasmin plays a role in iron homeostasis, and its activity impairment leads to iron accumulation in liver, pancreas, and brain. Iron deposition promotes diabetes, retinal degeneration, and progressive neurodegeneration.

    Related Conference of Ceruloplasmin replacement therapy

    September 28-29, 2018

    2nd International Conference on Diabetes and Diabetic Nursing Care

    Montreal, Quebec, Canada
    November 21-22, 2018

    14th World Congress on Endocrinology & Diabetes

    Paris, France
    November 26-27, 2018

    26th International Diabetes and Healthcare Conference

    Helsinki, Finland
    November 26-27, 2018

    13th European Diabetes and Endocrinology Congress

    Dublin, Ireland

    March 28-29, 2019

    21st Asia Pacific Diabetes Conference

    Osaka,Japan
    May 16-17, 2019

    2nd Global Meeting on Diabetes and Endocrinology

    Abu Dhabi, UAE

    28th European Diabetes Congress

    June 10-11, 2019 | Edinburgh, Scotland
    July 24-25, 2019

    29th World Diabetes & Heart Congress

    Melbourne, Australia
    Oct 03-04, 2019

    Euro Diabetes Congress & Expo

    | Paris, France

    Ceruloplasmin replacement therapy Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in